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anhedoniaBackground: Anhedonia, a symptom prevalent in schizophrenia patients, is thought to arise either within nega-
tive symptomatology or from secondary sources, such as depression. The common co-occurrence of these dis-
eases complicates the assessment of anhedonia in schizophrenia.
Method: In a sample of 40 outpatients with chronic schizophrenia, we explored both the validity of the Snaith-
Hamilton Pleasure Scale (SHAPS) self-report for anhedonia assessment and those factors influenced its scoring.
We assessed negative symptoms using the Brief Negative Symptom Scale (BNSS), depression symptoms using
the Calgary Depression Scale for Schizophrenia (CDSS) and cognitive impairment using the Brief Assessment of
Cognition in Schizophrenia (BACS), before exploring associations between these scales.
Results: The SHAPS was validated for use in schizophrenia. SHAPS scores were not associated with negative
symptoms or cognitive impairment, but were linked to a single Depression symptom: Hopelessness (r = 0.52,
p b 0.001).
Conclusions: SHAPS scores, therefore, appear to only reflect anticipatory anhedonia arising from the affective do-
main. We advocate the development of multi-faceted self-report measures to more holistically assess anhedonia
in schizophrenia.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction
Anhedonia – an impaired ability to experience pleasure [1] – fea-
tures centrally in several psychiatric conditions, and significantly im-
pacts quality of life [2]. It is a notable aspect of schizophrenia [3],
where it is conceptualised as one of the disease's ‘negative symptoms’
(alongside amotivation, asociality, blunted affect and alogia) [4], and
of Depression, where it is understood as one of two core features of
the condition [5,6].
Such is anhedonia's importance in schizophrenia that it has been
suggested to be one of only two features underpinning negative
symptomology [7], though others have suggested that such conclusions
may be premature [8]. Regardless, in both Schizophrenia and Depres-
sion, anhedonia is poorly understood [9]. It is only within the last few(I. Jarratt-Barnham),
(E. Fernandez-Egea).
.
. This is an open access article underdecades that the symptom has become the subject of significant
research.
Recent work has identified the presence of several distinct facets
within the symptom. Anhedonia is conceptualised primarily as com-
prising of two aspects: 1) consummatory anhedonia – a reduction in
pleasure arising fromongoing activities – and 2) anticipatory anhedonia
– a reduced anticipation of future pleasure [10,11]. In schizophrenia, an-
hedonia is thought principally to comprise the latter; anticipatory im-
pairment [12].
This deficit is often understood as an impaired ability to report past
and projected future experiences [13]. This understanding is supported
by substantial cognitive neuroscience research, which has demon-
strated that anticipating future experience is dependent on neural pro-
cesses linked to episodic memory [14], functions impaired in
schizophrenia [15].
Chronic schizophrenia patients, however, frequently present not
only with primary negative symptoms, but alsowith secondary, comor-
bid depression [16]. Not only are both these diseases strongly associated
with anhedonia, but both these diagnoses are specifically linked to an
anticipatory impairment [17]. The co-occurrence of these diseasesthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Demographic and clinical features of our sample.
Gender (male) [n (%)] 36 (90)
Age [mean (SD)] 46.55
(10.17)
Illness duration (years) [mean (SD)] 24.65
(8.53)







Blunted affect 4.7 (5.0)
Alogia 3.3 (3.2)
BACS normalized Z-scores – corrected for gender and age in a









Tower of London −0.68
(1.34)
CDSS Total score [mean (SD)] 3.15 (3.14)
SHAPS Total score [mean (SD)] 23.4 (5.77)
BNSS indicates Brief Negative Symptoms Scale; BACS: Brief Assessment of Cognition in
Schizophrenia; CDSS: Calgary Depression Scale for Schizophrenia; SHAPS: Snaith-Hamil-
ton Pleasure Scale; SD, standard deviation.
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targeting of treatment for, anhedonia in schizophrenia.
Anhedonia's assessment in schizophrenia is also hampered by two
features of scales used in the symptom's evaluation. Firstly, there exists
a substantial heterogeneity in rating criteria across assessment tools
[18]. For instance, anhedonia is rated alongside asociality in the Scale
for the Assessment of Negative Symptoms (SANS) [19], rated individu-
ally by 5 distinct items in the Clinical Assessment Interview of Negative
Symptoms (CAINS) [20] and is not featured at all in the negative sub-
scale of the Positive and Negative Symptom Scale (PANSS) [21].
There is also a substantial lack of convergence between anhedonia
measures [18]. Strauss and Gold found low convergence across
clinician-rated assessments of anhedonia [22], and such assessments
are only moderately associated with anhedonia self-report measures
[23,24].
This variation across assessment measures complicates the study of
anhedonia, and has prompted calls for work investigating whether dif-
ferent assessments in fact explore distinct aspects of the symptom [18].
In this work, we explore anhedonia assessment as conducted by the
Snaith-Hamilton Pleasure Scale (SHAPS) [25]. The SHAPS is a widely
used, 14-item self-report assessing anticipatory anhedonia. Each item
begins ‘I would’, and is answered via four response categories (‘Defi-
nitely Agree’, ‘Agree’, ‘Disagree’, ‘Strongly Disagree’). Higher scores indi-
cate greater severity of anhedonia. The content of each item is intended
to keep age, gender and cultural bias to a minimum.
The last decade has seen a revitalised interest in the SHAPS, with
work validating it for use in a wide range of languages [26–30] and in
a number of clinical populations. These include Parkinson's [29],
major depression [31] and schizophrenia [30,32]. However, no
work exists exploring the SHAPS' relationship to recent measures
of negative symptomology that distinguish between anhedonia sub-
types (e.g. the Brief Negative Symptom Scale), nor to Schizophrenia-
specific affective disorder assessments (e.g. the Calgary Depression
Scale). It is, therefore, unclear whether the SHAPS better reflects an-
hedonia associated with negative symptomology, or with secondary
depression.
Here, we investigate the influences affecting anhedonia self-report
in forty UK chronic schizophrenia patients by assessing the SHAPS' con-
vergence with ratings of negative and affective symptoms. Additionally,
we explorewhether the SHAPS is associatedwith cognitive impairment,
including memory deficit, as would be predicted were anhedonia in
schizophrenia to arise as a result of an impaired ability to report
projected future experiences [14,15].
2. Materials and methods
2.1. Design
This cross-sectional studywas part of a larger, transdiagnostic, study
of apathy and anhedonia (CHAPAS; 18/EE/0178) in schizophrenia.
2.2. Subjects
Participants were outpatients with chronic schizophrenia treated
with atypical antipsychotics, recruited from in and around Cambridge,
UK. Inclusion criteria were (1) being aged 18–65, (2) a diagnosis of
chronic schizophrenia, and (3) clinical stability, defined as no alteration
in antidepressant or antipsychotic medication within the last 8 weeks.
All participants provided written consent.
2.3. Assessments
As part of the larger study, all participants were assessed using the
following scales:
The SHAPS self-report assessed anhedonia and was scored ordinally
(‘Definitely Agree’=1, ‘Agree’=2, ‘Disagree’=3, ‘StronglyDisagree’=4); an approach yielding greater internal consistency than Snaith's orig-
inal scoring (either ‘disagree’ response=1, either ‘agree’ response=0)
[30].
The clinician-rated Brief Negative Symptom Scale (BNSS) [4]
assessed negative symptomatology. This 13-item measure contained 3
items assessing anhedonia, rating (1) consummatory anhedonia's fre-
quency, (2) intensity, and (3) anticipatory anhedonia. Each item was
scored 0–6, with 6 indicating greatest impairment.
The 9-item, clinician-rated Calgary Depression Scale in Schizophre-
nia (CDSS) [33] assessed affective symptoms, including circadian
rhythms, emotional and cognitive symptoms. Both CDSS and BNSS rat-
ings were blind to SHAPS results.
Cognitive assessments were conducted using the Brief Assessment
of Cognition in Schizophrenia (BACS) [34]. Patients' BACS scores were
compared to the general population's, matched for gender and age,
and below are expressed as z-scores.2.4. Statistical analyses
Analyses were performed using Matlab R2018b, except for factor
analysis (performed using JASP 0.10.0.0.). We divided our analysis into
3 parts, assessing:
The SHAPS' internal consistency, using Cronbach's Alpha, and struc-
ture, using an exploratory factor analysis (EFA) with an orthogonal
varimax rotation.
Relationship of SHAPS total score to (i) each BNSS subscore, (ii) each
individual BNSS anhedonia item, (iii) CDSS total score, and (iv) each in-
dividual CDSS item, by performing bivariate correlations using
Spearman's rank coefficient.
Relationship of SHAPS total score to BACS subscores reflecting pa-
tient memory; Verbal Memory, Symbol Coding, Digit Sequencing and
Tower of London subscores, by performing bivariate correlations using
Spearman's rank coefficient.
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Our sample (n = 40) had a mean age of 46.35 years (sd = 10.12),
and was 90% (n=36) male. All patients were medicated using atypical
antipsychotics. Table 1 reports sample characteristics and assessment
descriptive statistics. There were no differences between obtained
mean assessment scores and those reported in previous work: BNSS;
[4,35]; CDSS: [36]; SHAPS: [27,30].
The SHAPS achieved a Cronbach's Alpha of 0.76, indicating good in-
ternal consistency, and a Kaiser-Meyer-Olkin score of 0.77, indicating
that our sample was of sufficient size for factor analyses [37]. EFA anal-
ysis identified two factors with eigenvalues exceeding 1. A screeplot
suggested a two-factor structure underpinning our data.
SHAPS total was not significantly associated with any BNSS subscale
total; anhedonia (r = 0.13, p = 0.42), alogia (r = 0.039, p = 0.81),
blunting (r= 0.066, p= 0.69), asociality (r =−0.091, p= 0.58), dis-
tress (r=0.14, p= 0.4) or avolition (r=0.030, p=0.85), nor with in-
dividual anhedonia subscale items (consummatory anhedonia
frequency (r= 0.15, p= 0.35), intensity (r= 0.12, p= 0.47) or antic-
ipatory anhedonia (r= 0.08, p = 0.64)). There was also no significant
association with CDSS total score (r= 0.27, p= 0.091).
However, SHAPS total was significantly correlated with a single
CDSS item: ‘Hopelessness’ (r = 0.52, p b 0.001). This correlation
remained significant even after correction for multiple comparisons
using the Bonferroni Correction (α = 0.05/23 = 0.0022,
0.001 b 0.0022). The Hopelessness item reads: “How do you see the fu-
ture for yourself? Can you see any future, or has life seemed quite hope-
less? Have you given up or does there still seem some reason for
trying?”.
BACS scores were missing for 4 patients, leaving a sample of 36 (33
male, mean age= 46.97, sd= 9.57). No significant associations between
SHAPS total and BACS subscores were found: Verbal Memory (r =
−0.0036, p=0.98), Symbol Coding (r=0.07, p=0.68), Digit Sequenc-
ing (r= 0.036, p= 0.83), Tower of London (r=−0.073, p= 0.67).
4. Discussion
This study examined the influences determining anticipatory anhe-
donia self-report scores in a sample of chronic schizophrenia outpa-
tients. The SHAPS showed good internal consistency, suggesting it
successfully explored patient anhedonia. The two-factor SHAPS struc-
ture we identified does not replicate those results previously obtained,
which have instead reported either a one-factor or a three-factor struc-
tures for the measure [30,38]. Such work, however, was conducted on
samples markedly different from our own (e.g. in general psychiatric
or healthy samples).
SHAPS assessment was unrelated to both negative symptomology
assessment (BNSS) and memory impairment, but was significantly as-
sociated with one depression symptom: Hopelessness.
The lack of significant association between BNSS and SHAPS scores
suggests that the SHAPS does not capture anhedonia arising from the
core schizophrenic disorder. Absence of significant association with
cognitive impairment also supports this conclusion, as a deficit in epi-
sodic memorywould be expectedwere negative symptoms responsible
for anhedonia identified by the SHAPS.
This lack of association is in contrast to previous findings, which
have identified correlations between negative symptom measures and
SHAPS scores [32,39]. Our analysis, however, is the first to investigate
the SHAPS in relation to the BNSS specifically, and indeed the first to as-
sess the SHAPS' relationship with any second generation negative
symptom measure.
However, an alternative interpretation of the lack of correlation be-
tween the SHAPS and BNSS might point to conceptual differences be-
tween BNSS and SHAPS items. Whilst the BNSS asks patients to
generate and evaluate personal experiences, the SHAPS instead pro-
vides a specific list of experiences for evaluation. Plausibly, therefore,the SHAPS might ask patients to estimate future enjoyment of experi-
ences they have never had, resulting in inaccurate estimates and dispar-
ity between SHAPS and BNSS scores.
That said,we consider the experiences listed in the SHAPS so ubiqui-
tous (e.g. ‘I would enjoy a cup of tea or coffee or my favourite drink’),
that patients are very likely to have had them. Therefore, the SHAPS
and BNSS are not notably conceptually different, both requiring patients
to estimate their future enjoyment of an experience based on its past
enjoyment.
The significant association we identified between SHAPS and
CDSS Hopelessness deserves further consideration, particularly in
the context of the challenging living conditions faced by chronic
schizophrenia patients. Due to social isolation, poor physical health
and financial difficulties, these individuals often experience poor
quality of life [40]. Such exposure to social defeat [41] may present
as hopelessness and lack of anticipatory anhedonia, as identified by
the CDSS and SHAPS.
Our findings highlight the complexity of assessing symptoms, like
anhedonia, which are multifaceted and present in several clinical enti-
ties. Whilst we replicate work showing the SHAPS to successfully assess
anhedonia in schizophrenia [30], we also identified the SHAPS as only
exploring a single facet of the symptom, anticipatory affective anhedo-
nia. The ability of the SHAPS to holistically assess anhedonia in chronic
schizophreniamay, therefore, be limited. This highlights the need to de-
velopment of novel scales with both the capacity to validly assess mul-
tiple aspects of anhedonia, and able to evaluate the symptom
transdiagnostically, which should be a focus of future work.
Our study is limited, however, by its small sample size and by the
utilisation of only a single clinician to conduct clinician-rated patient as-
sessment. Larger samples and multiple raters would benefit future ex-
ploration of the influences determining anhedonia self-report.
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